Key result
Renal dysfunction reduced ACE inhibitor prescription (74% vs 83%, p<0.001) and respiratory disease reduced beta-blocker prescription (32% vs 53%, p<0.001) in patients with heart failure and LVSD.
Why the study?
How do co-morbidities affect the prescription of neurohormonal antagonists in patients with left ventricular systolic dysfunction?
Observational (n=3,658)
Yes
How do co-morbidities affect the prescription of neurohormonal antagonists in patients with left ventricular systolic dysfunction?
Absolute Event Rate: 74% vs 83%
p-value: p=<0.001
Relevant co-morbidities such as renal dysfunction and respiratory disease significantly reduce the prescription of life-saving neurohormonal antagonists in patients with LVSD, despite often not being valid contra-indications.
No takes yet. Share an insight, caveat, or question.
Comorbidities may limit neurohormonal antagonist use in LVSD; leaves open whether targeted interventions improve prescribing rates.
Lainščak et al. (2006) conducted an observational in Heart failure with left ventricular systolic dysfunction (n=3,658). Co-morbidities (renal dysfunction, respiratory disease) vs. Absence of specific co-morbidities was evaluated on Prescription of ACE inhibitors at discharge in patients with vs without renal dysfunction (p=<0.001). Renal dysfunction reduced ACE inhibitor prescription (74% vs 83%, p<0.001) and respiratory disease reduced beta-blocker prescription (32% vs 53%, p<0.001) in patients with heart failure and LVSD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: